All In Biotech

Drug Trial Radar · NCT04023227

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy. The Study is Also Know as Prevention And Reduction of Adverse Outcomes in Chagasic Heart failUre Trial Evaluation (PARACHUTE-HF).

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 922 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

922

Actual

Start

Dec 10, 2019

Primary completion

Mar 16, 2025

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by chronic Chagas' cardiomyopathy (CCC).

Conditions

  • Chagas Disease
  • Heart Failure

Interventions

  • Sacubitril/valsartanDrug

    Participants randomized to sacubitril/valsartan who were previously treated with angiotensin-converting enzyme inhibitors (ACEIs) had a 36-hour washout prior to receiving oral treatment with 50, 100, or 200 mg, film-coated tablets.

  • EnalaprilDrug

    Oral treatment with 5 or 10 mg tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12Time frame: Total follow-up time up to approximately 36 months
  2. Percentage of Participants Who Died From Cardiovascular CausesTime frame: Total follow up time up to approximately 36 months
  3. Percentage of Participants With First Hospitalization for Worsening Heart FailureTime frame: Total follow up time up to approximately 36 months
  4. Change From Baseline to Week 12 in NT-proBNP LevelsTime frame: Baseline to Week 12

Locations

79 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Corrientes, Argentina

  • Novartis Investigative Site

    Formosa, Argentina

  • Novartis Investigative Site

    Formosa, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Santiago del Estero, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Ramos Mejía, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Martín, Buenos Aires, Argentina

  • Novartis Investigative Site

    Temperley, Buenos Aires, Argentina

  • Novartis Investigative Site

    Villa María, Córdoba Province, Argentina

  • Novartis Investigative Site

    Salta, Salta Province, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, San Miguel de Tucuman, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    San Miguel Tucuman, Tucumán Province, Argentina

  • Novartis Investigative Site

    San Miguel Tucuman, Tucumán Province, Argentina

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Brasila, Federal District, Brazil

  • Novartis Investigative Site

    Brasília, Federal District, Brazil

  • Novartis Investigative Site

    Brasília, Federal District, Brazil

  • Novartis Investigative Site

    Goiânia, Goiás, Brazil

  • Novartis Investigative Site

    Goiânia, Goiás, Brazil

  • Novartis Investigative Site

    Goiânia, Goiás, Brazil

  • Novartis Investigative Site

    São Luís, Maranhão, Brazil

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.